- New total cash position of approximately CHF 210 million that is expected to extend cash runway to Q3 2021, excluding potential incoming milestones
- Financial position strengthened after Q2 close due to issuance of new shares, raising gross proceeds of USD 117.5 million
- Crenezumab: Phase 3 trial CREAD 2 fully recruited in July 2018; new Phase 2 data analysis provides strong evidence for principal target engagement of Abeta oligomers
- Selection of small molecules targeting Tau (Tau MorphomersTM) for clinical development in Alzheimer's disease
AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced financial results for the second quarter and first half ended June 30, 2018.
Read the full media release below.